Alzheimer's disease (AD) is the most common form of dementia, with prevalence progressively increasing with aging. Pathological hallmarks of the disease include accumulation of amyloid b-protein (Ab) peptides and neurofibrillary tangles in the brain associated with glial activation and synaptotoxicity. In addition, AD involves peripheral and brain endogenous inflammatory processes that appear to enhance disease progression. More than a decade ago a new therapeutic paradigm emerged for AD, namely the activation of the adaptive immune system directly against the self-peptide Ab, aimed at lowering its accumulation in the brain. This was the first time that a brain peptide was used to vaccinate human subjects in a manner similar to classic viral or bacterial vaccines. The vaccination approach has taken several forms, from initially active to passive and then back to modified active vaccines. As the first two approaches to date failed to show sufficient efficacy, the last is presently being evaluated in ongoing clinical trials. The present review summarizes the immunogenic characteristics of Ab in humans and mice and discusses past, present and future Ab-based immunotherapeutic approaches for AD. We emphasize potential pathogenic and beneficial roles of CD4 T cells in light of the pathogenesis and the general decline in T-cell responsiveness evident in the disease.
Introduction
Alzheimer's disease (AD) is the most common form of dementia in the elderly, characterized by progressive memory loss and cognitive decline. One of the primary pathological features of the disease, in addition to neurofibrillary tangles, dystrophic neurites and significant neuronal loss in affected brain regions, is the extracellular aggregation of the amyloid b-protein (Ab) peptide in the brain. [1] [2] [3] [4] Amyloid-b is produced from the amyloid precursor protein (APP) following proteolytic cleavage by band c-secretases. Mutations in the preseneline-1 gene (PS1), which encodes for a transmembrane protein that functions as part of the c-secretase complex, are associated with increased production of Ab42 over the less aggregative form Ab40, and are considered among the primary causes of early-onset familial AD. 5, 6 A growing body of evidence demonstrates that Ab plaques induce an inflammatory reaction in the brain, [7] [8] [9] whereas oligomeric forms of Ab exert synaptotoxicity. 3, 4, 10 In addition, in recent years information has accumulated demonstrating the marked pathological effects of Ab on brain vasculature, a phenomenon termed cerebral amyloid angiopathy, that causes vascular inflammation, brain haemorrhages, compromised perivascular drainage and altered blood flow. [11] [12] [13] Inflammatory processes such as microgliosis, astrocytosis, dystrophic microglia, complement activation, cytokine elevation and acutephase protein changes are thought to represent, at least in part, a response to the accumulation of Ab in the vasculature and parenchyma of the brain. A compromised immune system associated with aging may substantially impact on these processes and lead to compromised brain function and neuronal repair processes, which enhance the progression of AD. The current review summarizes the existing knowledge regarding the characteristics of Ab-reactive CD4 T cells in animal models and in humans, and discusses Ab-based immunotherapeutic approaches for AD in the context of disease pathogenesis and immunosenescence.
Main body

Ab autoimmunity in humans and mice
More than a decade ago a new concept emerged in the study of AD, namely eliciting adaptive immune responses to attenuate the accumulation of Ab in the brain. This was the first time that a self peptide was introduced to the body as a vaccine, similar to classic vaccination approaches used against various pathogens. As this approach may have brought about the most promising therapeutic approach for AD, it also challenged our previous knowledge of autoimmunity, immune tolerance and brain-immune interactions.
Amyloid-b-specific immunotherapy can considerably reduce amyloid burden and improve cognitive functions in animal models of AD. [14] [15] [16] [17] [18] [19] [20] [21] Although pre-clinical studies have proved successful, an initial clinical trial of active Ab vaccine (AN-1792 trial performed by Elan) was halted because of the development of severe inflammatory reactions in the brains of some vaccinated AD patients. [22] [23] [24] The severe side-effects were attributed to the use of the full length of the Ab peptide together with QS21, a very strong adjuvant, the combination of which presumably led to the occurrence of pathogenic T cells at the brain vasculature and parenchyma. 22, 23, 25 Nevertheless, the study of Ab-reactive T cells is key to unravelling their occurrence and characteristics in healthy humans as well as in patients with AD, and hence a key to designing safer immune-based approaches for AD therapy.
Although the general dogma would not anticipate the occurrence of effector Ab-reactive CD4 T cells in the circulation of human subjects, not only were they detected in almost all individuals tested but significantly more elderly subjects and AD patients showed strong Ab-reactive T-cell responses compared with middle-aged subjects. 26 The Ab T-cell responses were primarily HLA-DR-dependent, and the presented T-cell epitopes derived primarily from residues 15-42 of Ab (see Table 1 ). About 20% of all the subjects were found to bear HLA-DR alleles, which either did not stimulate Ab-reactive T-cell lines or induced only a mild response. The great variability of HLA-DR alleles in humans, which is associated with multiple Ab T-cell epitopes, 26, 27 presumably reflects a great variability in the magnitude of T-cell activation in humans and therefore the variations in specific Abantibody titres evoked in AD patients following Ab42 vaccination. 28, 29 In human subjects, Ab T-cell epitopes were analysed in isolated peripheral blood mononuclear cells stimulated initially with Ab1-42 and thereafter with 15-residue-long overlapping peptides between 1 and 42 residues of Ab. T-cell responsiveness was measured by the magnitude of antigendriven T-cell proliferation and cytokine production following immunization. In humanized mice bearing the DRB1 1501 and 0401 alleles, peptides between residues 25 and 42 and between residues 18 and 32 served as the dominant T-cell epitopes, as observed also for T-cell lines derived from human subjects with these HLA genetic backgrounds. 26 Ab42 immunization of humanized HLA-DR4 and HLA-DR3/DQ8 transgenic mice evoked Ab-reactive T-cell responses which could be partially stimulated by Ab1-16, 32 and DRB1 0101 humanized mice elicited T-cell responses to an epitope between residues 1-28. 113 Since overlapping peptides between residues 15 and 42 of Ab were not used in these studies, it is unclear whether additional weak T-cell epitopes are located at the N-terminus of Ab or whether a truncated portion of the epitope was presented to the T cells
Animal models allow one to more accurately investigate the contribution of an MHC class II genetic background to Ab immunogenicity associated with the dominant epitope presented to T cells. They also allow a more efficient examination of the effect of various vaccination paradigms (i.e. route of administration and choice of adjuvant) on the dynamics and characteristics of the immune response elicited (i.e. antibody isotype and titres, and the profile of T-cell cytokines). In mice, Ab immunogenicity markedly differs between strains; for example, Ab is highly immunogenic in NOD and SJL mice, which have a dominant T-cell epitope between residues 10 and 24 of Ab, whereas the peptide evokes only weak T-cell responses in C57BL/6 mice in which the epitope is between residues 16 and 30.
30-32 NOD congenic mice bearing the I-A b class II allele also fail to elicit a strong T-cell response, suggesting that the low immunogenicity of Ab 16-30 in C57BL/6 mice is primarily a result of a low-affinity epitope selected by the I-A b MHC class II. However, both C57BL/6 and B6.H-2 s congenic mice, but not SJL mice, exhibit enhanced Ab-specific T-cell responses upon the depletion of regulatory T (Treg) cells, suggesting that under certain genetic backgrounds, Treg cells can significantly affect Ab immunogenicity. 31 As no differences in thymic expression of APP are observed between C57BL/6 and SJL mice, the mechanism behind the effect of Treg cells on Ab immunogenicity in C57BL/ 6 mice and the reason it is not effective in the more Abimmunogenic SJL mice are yet to be revealed.
Overall, T-cell epitopes markedly vary between mice and humans, with multiple epitopes located primarily between Ab residues 10 and 30 and between 15 and 42, respectively. Both MHC class II alleles and Treg cells are crucial for determining the strength and phenotype of the adaptive immune response to Ab following immunization. The fact that almost all human subjects possess Abreactive T cells in their circulation and that these tend to expand with age and with the progression of AD raises a number of questions that are yet to be answered. (i) Are these Ab-specific T cells positively selected in the thymus or do they simply 'escape' negative selection? (ii) Do Abreactive T cells play a role in the progression of AD and, if so, how? (iii) Can they be externally stimulated to beneficially halt the progression of AD? Clearly, Ab-reactive T cells are activated upon immunization and induce Ab antibody production, however, one should consider the great variability in T-cell responses that can be anticipated in humans; in fact, this variability may perhaps be translated to personalized medicine.
Ab-based vaccines
Since Ab T-cell epitopes are located primarily between residues 10 and 42 of Ab in mice and in humans, N-terminal portions of Ab, namely fragments within residues 1-15 comprising dominant Ab B-cell epitopes, have been used to generate active Ab vaccines (Fig. 1) . 17, 18, [33] [34] [35] These peptides were conjugated to carriers such as albumin 34, 36 or the promiscuous foreign T-cell epitope PADRE 37 and were shown to elicit effective Ab antibody responses without stimulating an Ab-specific T-cell response. These vaccination studies have led to pre-clinical studies using the N-terminal portion of Ab presented on the surface of virus particles 38 or liposomes, 39 or administered as Ab-coding DNA plasmids or viral vectors, 35, [40] [41] [42] and current clinical trials using such N-terminus Ab peptides conjugated to diphtheria toxin or tetanus toxin are being carried out. The non-self carriers in these vaccines, although they avoid the T-cell response against Ab, presumably evoke a strong T-cell response against the foreign epitopes and high titres of Ab-specific antibodies (Fig. 1) . In contrast to non-self carriers, our group generated a conjugate of Ab1-15 and heat-shock protein 458 (hsp 458), a 17-amino-acid residue peptide derived from hsp 60. 43 Compared with Ab1-42, Ab-hsp 60 immunization of humanized mice carrying the HLA-DR allele DRB1*DR1501 evoked a very mild T-cell response, evident by a significantly lower production of interferon-c (IFN-c) and interleukin-17 (IL-17) by draining lymph node-derived T cells. 44 Notably, the mild T-cell response induced by Ab-hsp 60 induced a gradual increase in specific Ab antibody titres, which were sufficient for effective clearance of Ab plaques from the brain of aged APP-transgenic mice. In addition to its function as a T-cell epitope, 43, 45, 46 hsp 458 also activates the Toll-like receptor 4 pathway 47 and so T-cellindependent antibody production evoked by Ab-hsp 60 immunization is plausible.
Clinical trials using either Ab42 active vaccination or anti-Ab passive vaccination have so far failed to show treatment efficacy, so eliciting a beneficial adaptive immune response to Ab appears to be more complicated than was originally thought. Indeed, clearance of Ab plaques in mouse models of AD may be partially misleading because it may not accurately represent key pathological features of the disease. This could have several explanations. (i) Most animal models of AD are treated prophylactically (i.e. in a prevention mode) or following the initial Ab deposition in the brain. They are rarely, if at all, conducted in ages and disease stages equivalent to human AD patients, in which immunity declines and brain inflammation is markedly enhanced. (ii) The increase in Ab42/40 ratio in some mouse models of AD induces a more condensed form of plaques where the capacity of Ab clearance in the brain is considerably reduced. 48, 49 This may represent a shift towards a fastprogressing form of AD where Ab antibodies, either naturally occurring or generated following vaccination, are insufficient to promote a therapeutic effect. in AD patients may be facilitated by the Ab-specific antibodies depending on their titers, epitope specificity, the Fc glycosylation pattern or the type of Fc receptor. [50] [51] [52] In addition, a robust expansion of Ab-specific B cells occurs, which may lead to ectopically enhanced activation of pathogenic Ab-specific T cells (Fig. 1). (iv) The loss of synapses and neurons, which leads to progressive cognitive decline throughout the course of AD, is moderate in most mouse models of the disease, so the impact of Ab clearance on this key aspect of the disease is unclear. Stimulating an immune response that promotes Ab clearance as well as neuronal repair (e.g. via cytokines and neurotrophic factors [53] [54] [55] ), which may be administered in a prevention mode, may therefore be considered a future goal for AD immunotherapy. Factors such as the vaccine carriers (either derived from self or non-self proteins), the routes and timing of vaccine administration and the choice of adjuvants may substantially decrease some of the risks described above and therefore improve treatment efficacy. be boosted to promote pathogenic autoimmunity. In the following section we discuss the molecular and cellular setting that drives the homing of Ab T cells to the brain and whether such a process can be used to enhance neuronal repair mechanisms in the aging and diseased brain. The role of T cells in the brain has been widely studied in recent years. Trafficking T cells to the brains of APPtransgenic mice over-expressing transforming growth factor-b or IL-1b did not cause cellular or behavioural abnormalities 56,57 and brain-specific T cells have been shown to play beneficial roles in murine models of brain injury, 58, 59 amyotrophic lateral sclerosis 60 and stroke. 61 Such specific T cells, or the cytokines they produce, participate in numerous activities such as increasing the uptake of Ab plaques, 30, 62, 63 releasing regulatory cytokines, 55 increasing the expression of neurotrophic factors, 54, 64, 65 increasing the buffering capacity of glutamate 66 and enhancing neurogenesis. 53, 54, 67, 68 Our group has recently demonstrated that Ab-reactive T cells are able to effectively target Ab plaques in the brains of APPtransgenic mice and enhance the phagocytic activity of adjacent microglia (see Fig. 2 and refs 30 and 62), at least partially via IFN-c-induced TREM2 and SIRPb1 expression, which were recently suggested as DAP12-associated phagocytic receptors on microglia. 69, 70 Amyloid-b may be presented to T cells via co-localized MHCII high antigen-presenting cells, which either differentiate from brain-endogenous microglia or are recruited from the blood as a result of increased CCL2 expression. Interferon-c emerges as a unique cytokine, which on one hand facilitates T-cell migration into and within the brain parenchyma, [71] [72] [73] and on the other hand promotes immunoregulatory processes [74] [75] [76] and neuronal repair in the brain. 53, 66, 74, [77] [78] [79] [80] [81] [82] Provided that IFN-c signals to all neural populations, further research is required to determine how IFN-c orchestrates its various effects in the brain. Clearly, the overall amounts of IFN-c in the brain are crucial to shift its function from devastating at high levels 83 to beneficial at low levels. 53, 74, 78, 80 Additional cytokines such as IL-10 and transforming growth factorb, together with a profile of chemokines and neurotrophic factors secreted by the T cells, may prove therapeutic for the AD brain.
Ab-reactive CD4 T cells in brain inflammation and repair
Given the immunogenicity of Ab as demonstrated in humans and mice, it is clear that Ab-reactive T cells can
The specific mechanisms underlying the migration, activation and survival of the T cells within the brain parenchyma are yet to be identified. The model illustrated in Fig. 2 demonstrates that following Ab immunization, Ab-specific T cells target the brain vasculature in which Ab is deposited. Expression of IFN-c in the brain of a mouse AD model in limited amounts, which cause no spontaneous infiltration of bone marrow-derived cells, abnormal glial activation or neurological deficits, 53, 84 is required for the migration of T cells within the brain parenchyma. 30, 85 Three conditions can therefore promote Ab-specific T-cell entry to the brain parenchyma: (i) deposition of Ab at the brain vasculature, compromising the blood-brain barrier and inducing a local inflammatory reaction [86] [87] [88] (ii) the stimulation of Ab-specific T cells initially in the lymph node and then by perivascular and leptomeningial dendritic cells in the brain [89] [90] [91] [92] [93] [94] and (iii) low brain levels of IFN-c, which is perhaps a master regulator of T-cell adhesion, antigen presentation, chemokine expression and signalling and T-cell migration.
Previous findings have primarily implicated brain-specific CD4 T cells in the pathology of experimental autoimmune encephalomyelitis, a model for multiple sclerosis in which myelin-specific T cells penetrate the central nervous system and promote axonal demyelination. 91, [95] [96] [97] [98] Although not inducing an autoimmune disease, the lymphocytic reaction of both B and T cells to Ab is potentially pathogenic because of the risks of meningoencephalitis, 23 entry of cytotoxic CD8 T cells into the brain, strong pro-inflammatory cytokine profile of the CD4 T cells 99 and brain haemorrhages caused by Ab antibodies. [100] [101] [102] However, if the pathogenic capacity of Ab-specific T cells can be neutralized (for instance by stimulating a non-pathogenic cytokine profile) these T cells may play a beneficial role in promoting both Ab clearance and neuronal repair with minimal risk of adverse side-effects.
In summary, it is commonly accepted that effector and regulatory functions of lymphocytes are altered with aging 103, 104 and that further immune manifestations accompany the progression of AD. [7] [8] [9] 105, 106 Such alterations presumably increase the severity of infectious diseases and chronic inflammation and are reflected in the brain as increased levels of pro-inflammatory cytokines such as IL-1b, tumour necrosis factor-a and IL-6, which enhance neurotoxicity and may impair key functions of microglia in neuronal function and repair. [107] [108] [109] Most immune intervention approaches, although performed in mouse models of AD, do not fully address the aforementioned immune alterations occurring with aging and with the progression of AD, which may significantly impact the outcome of treatment. Future studies of immunotherapy may therefore consider the following approaches, separately or in combination with the Ab antibody treatment: (i) improving immunity through direct immune interventions (e.g. balancing key cytokines and chemokines) 110, 111 and through indirect approaches such as exercise, appropriate nutrition and stress management, which may significantly contribute to higher immune potency and regulation; (ii) effectively blocking prominent inflammatory cascades underlying auto-inflammation, such as those mediated by tumour necrosis factor-a or IL-1; and (iii) cell therapy (either with monocytes, dendritic cells or CD4 T cells directed at Ab or at other brain antigens) to facilitate the function of immune cells within the brain. Such immune interventions may reduce immune-mediated neuronal damage overall and enhance neuronal repair, aspects that may be crucial to achieve treatment efficacy in patients with AD.
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